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Introduction  
According  to  Garrido  et  al.  (2019),  every  year,  more  than  100  million  people  visit  or  
travel  to  high  mountain  areas  for  professional,  touristic,  sports  or  religious  reasons,  reaching  high  
altitudes.  However,  at  higher  altitudes,  the  decreased  partial  pressure  of  oxygen  can  cause  several  
pathological  presentations,  such  as  altitude  sickness.  The  most  common  of  which  is  Acute  
Mountain  Sickness,  also  known  as  AMS  (Prince  et  al.,  2021).  Acute  Mountain  Sickness  was  
clinically  classified  in  1913  by  the  British  doctor  Thomas  Ravenhill,  however  the  exact  
pathogenic  mechanism  or  the  conditions  that  set  AMS  into  motion  are  still  not  fully  understood  
(Garrido  et  al.,  2019).  Prince  et  al.  (2021)  suggest  that  Acute  Mountain  Sickness  is  caused  by  the  
body’s  reaction  to  the  reduced  oxygen  level  in  respired  air  and  results  in  tissue  hypoxia.  Garrdio  
et  al.  (2019)  suggest  that  the  most  feasible  mechanisms  are  encephalic  vasodilation,  vasogenic  
edema,  increased  intracranial  pressure  and  meningeal  distension  or,  simply  put,  an  increased  
swelling  of  the  centeral  nervous  system.  This  makes  sense  since  the  brain  is  the  most  sensitive  
organ  regarding  hypoxia  and  oxygen  stress  (Prince  et  al.,  2021).   
AMS  typically  occurs  at  an  altitude  of  greater  than  2500  meters  for  non-acclimated  
individuals;  however,  it  can  occur  at  lower  elevations  for  those  who  are  high-risk  (Ahluwalia  et  
al.,  2020).  AMS  typically  occurs  within  hours,  usually  4  to  12 h  after  arrival  at  a  new  altitude  
(Luka  et  al.,  2017).  AMS  may  progress  from  nonspecific  symptoms  to  life-threatening  
high-altitude  cerebral  edema  although  it  should  not  get  to  this  point  if  treated  (Meier  et  al.,  
2017).   Most  common  symptoms  inlcude  headaches,  nausea/vomiting,  light-headedness,  
insomnia,  and  fatigue  (Aksel  et  al.,  2019).  
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Diagnosis   
Diagnosis  of  AMS  is  commonly  based  on  the  use  of  the  Lake  Louise  Scoring  system  or  
LLS  (Burtscher  et  al.,  2021).  The  LLS  is  a  self-assessment  questionnaire  including  five  main  
symptoms:  headaches,  nausea,  dizziness,  fatigue,  and  difficulty  sleeping.  Each  symptom  is  rated  
with  a  score  from  0  to  3  with  0  for  no  discomfort,  1  for  mild,  2  for  moderate,  and  3  for  severe  
symptoms  (Burtscher  et  al.,  2021).  Another  form  of  diagnosis  is  VAS  or  the  Visual  Analog  Scale.  
This  is  known  for  measuring  changes  in  the  intensity  of  symptoms  such  as  headache  or  nausea  
(Frühauf  et  al.,  2016).  However  as  stated  by  Frühauf  et  al  (2016),  this  method  uses  few  
descriptive  words  and  generally  consists  of  a  continuous  100  mm  scale,  reaching  from  the  
non-occurrence  (left  side)  to  the  highest  intensity  of  possible  symptoms  (right  side).  Another  
form  of  diagnosis  is  the  AMS-C.  The  AMS-C  score  was  derived  from  the  Environmental  
Symptom  Questionnaire  (ESQ),  which  was  formulated  in  1979  to  assess  symptoms  induced  upon  
exposure  to  extreme  environmental  conditions  ( Ahluwalia  et  al.,  2020).  However  Ahluwalia  et  
al.  (2020)  go  on  and  explain  that  the   AMS-C  score  is  used  less  frequently  due  to  it  being  an  
intricate  assessment  tool.  
Risk  Factors  
Some  individuals  are  more  prone  to  the  occurrence  of  acute  mountain  sickness  (AMS)  
than  others.  Typically,  the  risk  factors  include  the  rate  of  ascent  and  absolute  altitude  reached  
(Lawrence  and  Reid,  2016).  Other  risk  factors  for  AMS  include  age,  sex,  smoking,  and  obesity  
but  they  are  disputed  (Lawrence  and  Reid,  2016).  Suh  and  Flaherty  (2019)  stated  that  s ome  
studies  have  shown  advanced  age  to  be  protective  against  AMS,  whereas  others  have  found  no  
association  between  age  and  AMS.  Due  to  the  dispute  of  risk  factors,  many  other  factors  have  
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been  proposed;  for  example,  the  idea  that  endurance-trained  athletes  are  at  greater  risk  of  
developing  AMS.  Sareban  et  al.  (2019)  suggest  that  endurance-trained  athletes  with  a  high  
maximal  oxygen  uptake  may  be  at  increased  risk  for  AMS  due  to  the  possible  underlying  
mechanisms  which  include  a  training-induced  increase  in  resting  parasympathetic  activity,  higher  
resting  metabolic  rate  (RMR),  and  lower  hypoxic  ventilatory  response.  Interestingly,  at  the  end  
of  study,  it  was  found  that  endurance-trained  athletes  are  at  higher  risk  for  developing  AMS  on  
the  first  day  after  passive  and  rapid  ascent,  possibly  due  to  an  increased  parasympathetic  activity 
and  an  increased  RMR  (Sareban  et  al.,  2019).   
  Other  proposed  forms  of  risk  factors  that  can  increase  the  likelihood  of  AMS  occuring  
include  pre-existing  disease.  Prince  et  al.  (2020)  suggested  that  pre-existing  diseases  can  increase  
Acute  Mountain  Sickness  risk  by  magnifying  the  effects  of  hypoxia.  The  most  common  
conditions  include  anemia,  with  a  reduced  oxygen-carrying  capacity  of  the  blood,  and  chronic  
obstructive  pulmonary  disease,  due  to  the  reduced  degree  of  oxygenation  occurring  in  the  lungs  
(Prince  et  al.,  2020).  It  is  interesting  to  note  that  a  history  of  pre-existing  hypertension  is  
common  in  people  participating  in  mountain  activities  (Duke  et  al.,  2020).  Duke  et  al.  (2020)  
created  a  set  of  experiments  to  determine  the  relationship  between  hypertention  and  AMS  and  
found  no  relationship  between  measured  BP  values  and  AMS.  However,  their  results  suggest  that  
the  risk  of  AMS  may  be  lower  in  people  with  a  history  of  pre-existing  hypertension  (Duke  et  al.,  
2020).  
AMS  is  not  limited  to  just  physical  factors  but  also  includes  potential  psychological  
factors  ( Niedermeier  et  al.,  2017).  Exposure  to  high  altitude  may  lead  to  psychological  change  
such  as  anxiety,  the  most  prevalent  mood  state  associated  with  AMS  (Yu  et  al.,  2016).  Hüfner  et  
al.  (2019)  suggested  that  anxiety  at  high  altitudes  correlates  with  the  severity  of  insomnia  and  
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tachycardia.  High  levels  of  anxiety  before  high  altitude  exposure  were  associated  with  higher  
anxiety  during  the  climb  and  higher  levels  of  AMS  within  individuals  ( Hüfner  et  al.,  2019).  It's  
also  important  to  note  that  at  high  altitudes,  the  sleep  alterations  aggravate  anxiety  which  cause  a  
nightmarish  loop  which  increases  the  chances  of  AMS  in  individuals  (Yu  et  al.,  2016).  Lastly,  
Prince  et  al.  (2020)  stated  that  any  travelers  with  prior  episodes  of  Acute  Mountain  Sickness  are  
at  greater  risk  than  those  who  have  tolerated  similar  trips  in  the  past.  
Pathophysiology  of  AMS   
As  stated  before,  hypoxia  has  been  associated  with  increased  susceptibility  to  the  
neurological  syndrome,  known  as  acute  mountain  sickness  (Bailey  and  Ogoh,  2017).  Hypoxia  is  
known  to  be  caused  by  a  decrease  in  the  partial  pressure  of  oxygen  in  the  atmosphere.  Berger  et  
al.  (2020)  suggest  that  once  hypoxia  is  established,  it  may  cause  AMS  by  following  distinct  
pathways.  At  high  altitude,  cranial  blood  flow  (CBF)  increases  to  maintain  oxygen  delivery  to  
the  brain  (Berger  et  al.,  2020).  In  hypoxia,  CBF  is  determined  by  arterial  blood  pressure  and  by  
the  balance  between  pressure  of  oxygen  (Po2)  and  the  partial  pressure  of  carbon  dioxide  (Pco2),  
with  vasodilation  caused  by  hypoxemia  dominating  over  vasoconstriction  caused  by  hypocapnia  
(Berger  et  al.,  2020).  Berger  et  al.  (2020)  suggest  that  the  hypoxemia  in  AMS  induces  a  greater  
amount  of  cerebral  blood  flow,  meaning  that  there  will  be  an  increase  of  i ntracranial  pressure.  
Low  levels  of  partial  pressure  in  the  atmosphere  caused  by  hypoxia  increase  CBV  or  cerebral  
blood  volume  ( Gunga  et  al.,  2015).  This  makes  sense  since  the  increased  amount  of  blood  flow  
would  go  hand  in  hand  with  an  increase  of  CBV;  both  of  these  play  a  part  in  the  increase  of  
pressure  within  the  capillaries  and  ultimately  lead  to  vasogenic  edema  (Gunga  et  al.,  2015).  
Vasogenic  edema  is  defined  as  extracellular  accumulation  of  fluid  resulting  from  disruption  of  
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the  blood-brain  barrier  or  the  BBB  (Michinaga  and  Koyama,  2015).  Such  factors  cause  
insufficient  cerebrospinal  compliance  due  to  hypoxia-induced  brain  swelling.  The  swelling  
increases  intracranial  pressure  and  causes  brain  compression  and  headaches,  which  leads  to  
being  susceptibile  to  AMS  (Lu  et  al.,  2015).  
  Another  distinct  pathway  that  ultimately  can  lead  to  AMS  happens  yet  again  when  
partial  pressures  of  oxygen  (Po2)  fall  throughout  the  body  during  exposure  to  high  altitude  (Lu  et  
al.,  2015).  Lu  et  al.  (2015)  suggested  that  to  limit  the  drop  in  arterial  oxygen  content,  the  body  
immediately  reacts  by  increaing  cardiac  output  through  sympathetic  activation.  This  sympathic  
activation  causes  a  cascade  throughout  the  body,  ultimately  affecting  the  kidneys  and  increasing  
water  retention.  As  a  result,  this,  again,  leads  to  the  increase  in  capillary  pressure  and  then  
vasogenic  edema  (Lu  et  al.,  2015).  From  there,  the  body  is  again  susceptible  to  AMS.   
Lastly,  Lu  et  al.  (2015)  suggested  that  hypoxia-induced  hypoxemia  triggers  an  
inflammatory  response.  The  release  of  inflammatory  mediators  contributes  to  an  increase  in  
capillary  pressure  by  vasodilatation  and  overperfusion,  leading  to  a  disruption  of  the  BBB  and  
increased  BBB  permeability;  this  is  also  known  as  the  blood-brain  barrier  theory  (Lu  et  al.,  
2015).  
Prevention  of  AMS   
The  most  common  measures  to  be  considered  for  the  prevention  of  AMS  include  the  
following:  gradual  ascent,  acetazolamide  and  ibuprofen  ( Lukas  et  al.,  2019).  Dexamethasone  and  
inhaled  budesonide  have  also  been  suggested  as  prevention  to  AMS  however  they  are  disputed  to  
whether  or  not  they  should  be  fully  considered  as  preventions  against  AMS  ( Lukas  et  al.,  2019) .  
Lukes  et  al.  states  that  these  recommendations  are  intended  to  apply  to  all  travelers  to  high  
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altitude,  whether  they  are  traveling  to  high  altitude  for  work  or  recreation.  Gradual  ascent  is  the  
best  prevention  strategy  to  prevent  all  forms  of  high  altitude  illnesses  (HAI)  since  the  major  risk  
factors  are  the  absolute  change  in  altitude  and  rate  of  ascent  (Aksel  et  al.,  2019).  Aksel  et  al.  
(2019)  also  stated  that  gradual  ascent  gives  sufficient  time  to  develop  an  adequate  degree  of  
altitude  acclimatization.  Controlling  the  rate  of  ascent,  in  terms  of  the  number  of  meters  gained  
per  day,  is  a  highly  effective  means  of  preventing  acute  altitude  illness;  however,  in  planning  the  
rate  of  ascent,  the  altitude  at  which  someone  sleeps  is  considered  more  important  than  the  
altitude  reached  during  waking  hours  ( Lukas  et  al.,  2019).  It's  important  to  state  that  one  must  be  
on  the  lookout  from  HAI  symptoms  because  proceeding  to  higher  sleeping  altitude  is  never  
recommended  for  an  individual  who  has  shown  symptoms  of  AMS  or  HAI  ( Aksel  et  al.,  2019).  
Acetazolamide  is  the  most  common  medication  used  for  acute  mountain  sickness  
prevention  ( Lipman  et  al.,  2020).  It  is  a  carbonic  anhydrase  inhibitor  which  can  help  an  
individual  acclimatize  quicker  (Kanaan  et  al.,  2017).  Gao  et  al.  (2021)  created  a  study  following  
the  effects  of  acetazolamide  and  found  that  acetazolamide  is  an  effective  prophylaxis  for  the  
prevention  of  AMS  in  doses  of  125,  250,  and  375  mg/bid.  The  greater  the  doses  of  acetazolamde  
cause  more  frequent  and  pronounced  side  effects  and  they  do  not  convey  greater  efficacy  
therefore,  the  recommended  adult  dose  for  acetazolamide  is  125  mg  every  12  hours  (Lukas  et  al.,  
2019).  Interestingly,  a  study  was  done  to  compare  a  lower  dose  to  the  recommended  dose.  The  
study  found  that  a  reduced  dose  of  acetazolamide  of  62.5  mg  is  as  effective  as  the  currently  
recommended  dose  of  125  mg  for  the  prevention  (McIntosh  et  al.,  2017).  
Ibuprofen  can  be  used  for  AMS  prevention  in  persons  who  do  not  wish  to  take  
acetazolamide,  have  allergies,  or  have  an  intolerance  to  acetazolamide  (Lukas  et  al.,  2019).  Irons  
et  al.  (2020)  created  a  double-blinded,  randomized,  field-based  clinical  trial  of  metoclopramide  
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and  ibuprofen  to  check  how  well  they  preventeted  AMS.  The  study  found  that  ibuprofen  was  
effective  at  reducing  AMS  symptoms,  including  headache  and  nausea,  but  that  metoclopramida  
was  more  effective  at  reducing  nausea  (Irons  et  al.,  2020).  Despite  this,  ibuprofen  is  still  
considered  a  useful  way  to  prevent  AMS.   
The  suggestion  of  dexamethasone  as  a  way  to  prevent  AMS  has  been  disputed,  with  a  
more  recent  study  done  by  Furian  et  al  (2018)  refuting  older  studies  regarding  its  usefulness.  
Likewise,  inhaled  budesonide  has  been  suggested  as  a  novel  prevention  for  acute  mountain  
sickness  yet,  efficacy  has  not  been  compared  with  the  standard  acute  mountain  sickness  
prevention  medication  such  as  acetazolamide  (Lipman  et  al.,  2018).  Therefore,  a  study  was  
conducted  comparing  budesonide  and  acetazolamide.  The  study  concluded  that  budesonide  was  
ineffective  for  the  prevention  of  acute  mountain  sickness  compared  to  acetazolamide  (Lipman  et  
al.,  2018).  Due  to  the  budesonide  constantly  being  proposed  as  a  way  to  prevent  AMS,  another  
study  was  done  in  order  to  further  test  its  ablililes  against  preventing  AMS.  But,  once  again,  the  
result  of  the  study  indicated  that  inhaled  budesonide  does  not  protect  against  AMS  or  severe  
AMS.  It  did,  however,  succeed  at  reducing  the  heart  rate  and  increasing  SPO2  without  any  side  
effects  within  the  individual  ( Zhu  et  al.,  2020).   
Treatments  for  AMS  
Potential  therapeutic/treatments  options  for  AMS  and  HACE  include  the  following:  
descent,  supplemental  oxygen,  portable  hyperbaric  chambers,  as  well  as  ibuprofen  and  
acetazolamide  ( Lukas  et  al.,  2019).  Treatment  of  mild  AMS  cases  are  usually  treated  with  
supportive  care  including  rest,  and  medications  for  headache  such  as  ibuprofen,  however  more  
severe  cases  can  be  treated  with  oxygen  given  through  a  nasal  cannula  as  well  as  with  
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prescription  medications  such  as  acetazolamide  (Jin,  2017).  Although  descent  remains  the  single  
best  treatment  for  AMS,  it  is  not  necessary  in  all  circumstances  and  therefore  individuals  
shouldn’t  descend  if  terrain,  weather,  or  injuries  make  descent  impossible  ( Lukas  et  al.,  2019).  If  
descent  is  required,  supplemental  oxygen  can  be  used  alongside  to  help  treat  AMS  symptoms  
although  not  necessary  (Davis  and  Hackett.,  2017).  If  descent  is  not  possible  or  if  AMS  is  
apparent  in  a  large  group  and  supplemental  oxygen  is  available,  then  the  oxygen  delivered  by  
nasal  cannula  should  be  sufficient  enough  to  relieve  symptoms  and  can  provide  a  suitable  
alternative  to  descent  ( Lukas  et  al.,  2019).   
Another  option  are  hyperbaric  chambers  or  portable  hyperbaric  chambers.  An  example  of  
a  portable  hyperbaric  chamber  is  the  Gammow  Bag.  The  Gammow  bag  is  the  most  important  and  
popular  device  used  in  most  trekking  and  high  altitude  expeditions  to  treat  and  prevent  AMS  
(Sun  et  al.,  2020).  The  Gammow  bag  is  an  inflatable  cylindrical  tube  made  of  heavy  rubber  or  
durable  fabric  that  pressurizes  the  atmosphere  sealed  within  it  to  that  of  a  much  lower  altitude  
(Sun  et  al.,  2020).  However,  the  Gammow  bag  is  not  always  an  acceptable  therapy  alternative  in  
a  predominantly  elderly  population  and  most  types  of  portable  hyperbaric  chambers  are  
monoplace  chambers  (Sun  et  al.,  2020).  This  means  that  they  would  not  be  efficient  within  a  
group  suffering  from  AMS.  Not  only  this,  but  hyperbaric  chambers  require  constant  tending  to  
by  care  providers  and  are  difficult  to  use  with  claustrophobic  or  vomiting  patients  ( Lukas  et  al.,  
2019).  Also,  symptoms  of  AMS  may  reoccur  when  individuals  are  removed  from  the  chambers  
yet  this  should  not  prevent  the  use  of  the  chamber  when  necessary  ( Lukas  et  al.,  2019).  However,  
in  many  cases,  ill  individuals  may  improve  sufficiently  to  enable  them  to  assist  in  their  
evacuation  and  descend  once  symptoms  improve  ( Lukas  et  al.,  2019).  Yet,  the  popularity  of  these  
chambers  have  not  dropped  and  due  to  this,  these  chambers  have  paved  the  way  for  new  chamber  
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ideas  such  as  a  newly  designed  multiplaced  hyperbaric  chamber.  Like  other  portable  hyperbaric  
chambers,  based  on  the  principle  of  increasing  ambient  pressure  within  the  chamber,  a  new  
multiplace  plateau  hyperbaric  chamber  has  been  designed  to  satisfy  the  needs  of  patients  who  
suffer  from  AMS  (Sun  et  al.,  2020).  Unlike  other  portable  hyperbaric  chambers,  atmospheric  
pressure  is  increased  by  adjusting  the  opening  of  the  expiration  valve  in  proportion  to  the  
ambient  pressure  (Sun  et  al.,  2020).  This  new  chamber  was  tested  and  the  results  found  that  the  
new  multiplace  plateau  hyperbaric  chamber  can  be  used  to  alleviate  plateau  hypoxia  by  
increasing  patient  PaO2  (Sun  et  al.,  2020).  However,  Sun  et  al.  (2020)  were  limited  in  their  
findings  and  could  not  find  the  value  of  the  chamber  for  treating  AMS  since  it  was  not  tested  in  
field  conditions.   
The  Pandemic  
With  the  current  COVID-19  pandemic  occurring  in  the  world,  clinicians  and  scientists  
have  suggested  therapies  for  the  coronavirus  disease-19  (COVID-19)  that  are  known  to  be  
effective  for  other  medical  conditions  ( Berger  et  al.,  2020).  Not  only  this,  but  other  clinicians  and  
scientists  have  suggested  similarities  between  other  medical  conditions  and  COVID-19  ( Berger  
et  al.,  2020) .  An  example  of  such  is  Soliz  et  al.  (2020)  who  stated  that  acute  mountain  sickness  
(AMS)  and  SARS-CoV-2  virus-induced  infection  share  striking  similarities  since  COVID-19  
may  cause  severe  hypoxia  in  the  absence  of  respiratory  distress  (Lari  et  al.,  2020).  Soliz  et  al.  
(2020)  suggested  that  even  though  AMS  and  COVID-19  have  different  pathogenic  mechanisms  
(barometric  hypoxia  vs.  viral  infection),  the  disease  progression  and  specific  symptoms  show  
remarkable  overlap.  More  specifically,  Soliz  et  al.  (2020)  suggested  that  both  illnesses  similarly  
trigger  a  perfect  storm  in  the  respiratory  system  which  affects  the  lungs  and  impair  oxygen  
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transport,  gas  exchange  and  the  neural  circuits  controlling  breathing.  Yet,  not  everyone  agrees  
with  such  claims.  Berger  et  al.  (2020)  disagree  and  suggest  that  while  the  hypoxemia  caused  by  
COVID-19  can  cause  symptoms  that  also  occur  in  AMS,  it  does  not  imply  that  similar  pathways  
in  AMS  are  involved  in  causing  hypoxemia  in  COVID-19.  Berger  et  al.  (2020)  also  presented  the  
fact  that  the  AMS  and  the  coronavirus  don’t  share  the  same  cardinal  symptom,  since  the  cardinal  
symptom  of  AMS  is  headache.  Lastly,  Berger  et  al.  (2020)  debated  the  difference  in  time  for  
symptom  onset  between  AMS  and  COVID-19,  with  AMS  symptoms  occurring  within  4-12  
hours  after  being  exposed  to  high  elevation  while  COVID-19  includes  an  incubation  period  from  
3-6  days  and  then  an  additional  8-12  days  for  symptoms  to  begin  ( Berger  et  al.  2020) .   
Conclusion  
With  the  amount  of  people  constantly  visiting  and  traveling  to  areas  of  high  elevation  for  
work,  sports  or  religious  reasons,  it's  safe  to  say  the  AMS  will  constantly  be  prevalent.  Because  
of  its  prevalence,  many  countermeasures  have  been  tested  and  studied  in  order  to  prevent  AMS.  
Although  the  exact  pathogenic  mechanisms  of  AMS  are  still  highly  debated/unknown,  it  is  often  
associated  with  hypoxia.  With  the  world's  current  pandemic,  more  research  is  going  into  AMS  
and  its  relationship  with  COVID-19.  
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